0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Changes in Mortality From Heart Failure—United States, 1980-1995 FREE

JAMA. 1998;280(10):874-875. doi:10.1001/jama.280.10.874.
Text Size: A A A
Published online

MMWR. 1998;47:633-637

2 figures, 1 table omitted

HEART failure is a disabling chronic disease and the leading principal diagnosis for hospitalization among older adults. Among the estimated 4.8 million U.S. residents who have heart failure, 70% are aged ≥60 years.1 During the past decade, the number of hospitalizations for heart failure have increased among Medicare beneficiaries,2 and these numbers are expected to increase with progressive aging of the U.S. population even though the case-fatality rate for heart failure is high. This report summarizes trends in mortality from heart failure in the United States for 1980-1995 and presents state-specific death rates for 1995 (the most recent year for which such data are available).

National mortality statistics are based on information from death certificates filed in state vital statistics offices and are compiled by CDC. Cause-of-death statistics are based on the underlying cause of death* recorded on the death certificate by the attending physician, medical examiner, or coroner in a manner specified by the World Health Organization and endorsed by CDC. Population estimates from the Bureau of the Census were used to calculate death rates for the U.S. population. Heart failure deaths were defined as those for which the underlying cause of death listed on the death certificate was International Classification of Diseases, Ninth Revision (ICD-9), code 428. This category includes congestive heart failure (ICD-9 code 428.0), left heart failure (428.1), and unspecified heart failure (428.9). Age-adjusted estimates were standardized to the 1970 U.S. population. Race-specific rates were limited to blacks and whites because numbers for other racial/ethnic groups were too small for meaningful analysis. The average annual percentage change in mortality from 1988 through 1995 was calculated as the 1995 rate minus the 1988 rate divided by the 1988 rate divided by seven and multiplied by 100.

From 1980 to 1995, the number of deaths with heart failure as the underlying cause increased from 27,415 to 46,484; in 1995, approximately 43,600 (94%) of these deaths occurred among adults aged ≥65 years. The overall rate changed from 10.3 in 1980 to 11.7 in 1995. Death rates for heart failure per 100,000 population were directly proportionate to age. For example, in 1995, age-specific rates were 633.5 for persons aged ≥85 years, 130.8 for persons aged 75-84 years, and 32.2 for persons aged 65-74 years. The rate for persons aged ≥85 years increased during 1980-1988 but declined slightly during 1989-1992. Similar small declines also were observed during the same period for adults aged 75-84 years and those aged 65-74 years.

For persons aged ≥65 years, age-adjusted death rates for heart failure increased during 1980-1988 and declined after 1988 in each racial and sex group. Age-adjusted rates for the U.S. population aged ≥65 years declined from 116.9 per 100,000 standard population in 1988 to 107.6 in 1995 (an average annual decline of 1.1% compared with 1988 rates). Among persons aged ≥65 years, age-adjusted rates for 1995 were 126.1 for black men, 117.0 for white men, 107.6 for black women, and 101.2 for white women. The largest average annual percentage decline compared with 1988 rates occurred among black men (3.0% per year), followed by black women (2.2%), white men (1.7%), and white women (0.5%). Because of greater declines in death rates for heart failure among black adults, from 1980 to 1995 the black:white ratio for men narrowed from 1.3:1 to 1.1:1 and for women from 1.4:1 to 1.1:1.

In 1995, age-adjusted death rates for heart failure among all ages varied substantially among the states and ranged from 3.4 (New Hampshire) to 29.7 (Mississippi). For persons aged ≥65 years, age-adjusted rates for 1995 ranged from 30.7 (New Hampshire) to 255.6 (Alabama).

REPORTED BY:

GA Haldeman, A Rashidee, R Horswell, Louisiana Health Care Review, Inc., Baton Rouge, Louisiana. Cardiovascular Health Br, Div of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

CDC EDITORIAL NOTE:

The findings in this report are consistent with a previously observed increase in age-adjusted death rates for heart failure during 1980-19883 that was followed by a decline after 1988. The decline suggests improved survival of older adults with heart failure or misdiagnosis of the underlying cause of death among adults with heart failure. For example, heart failure is five to six times more likely to be reported as a contributor rather than as the underlying cause of death on the death certificate.

Adults who survive a myocardial infarction or other hypertension-related diseases remain at increased risk for heart failure as they age. Among Medicare beneficiaries who are hospitalized for heart failure, hypertension is the secondary condition most commonly observed among black adults, and coronary heart disease is most common among white adults.2 Declines in death rates for heart failure during 1988-1995 among black adults and white men may reflect improved early detection of and changes in the therapeutic management of patients with hypertension,4 myocardial infarction,5 and heart failure.69 Since 1988, declines in death rates were greater among black adults than among white adults. Narrowing of the black-white ratio for heart failure mortality may reflect improved control of hypertension and access to medical care among older black adults.

Low numbers of deaths in some states should be interpreted with caution because they may reflect random variation. However, variations by state in death rates for heart failure also may reflect regional differences in the prevalence and treatment of predisposing conditions (e.g., hypertension, myocardial infarction, and other heart diseases) and variations in access to early diagnosis and therapeutic management of heart failure. Medical specialty differences in treating heart failure9 and state variations in mortality from heart failure suggest that national professional education initiatives may be needed to ensure that the clinical practice guidelines for evaluation and care of patients with heart failure are followed appropriately by all physicians to improve survival and reduce the risk for hospitalization through consistent pharmacologic management of this condition. Peer review organizations in states such as Louisiana10 have begun to assess statewide practices of evaluating and treating heart failure as the first stage for implementing standardized quality improvement efforts that will target the hospital care of all Medicare patients with heart failure.

Historically, the treatment of heart failure included combinations of diuretics and digitalis. Guidelines for clinical practice7,8 recommend a trial of angiotensin-converting enzyme (ACE) inhibitors for heart failure patients with left ventricular systolic dysfunction (i.e., an ejection fraction of ≤40%), unless specific contraindications exist, and use of diuretics for patients with volume overload. Digoxin should be initiated with ACE inhibitors and diuretics in patients with severe heart failure and should be added in patients who remain symptomatic despite optimal management with ACE inhibitors and diuretics.

Although mortality for heart failure is declining, an increasing number of older adults with heart failure will have a substantial impact on national health-care resources and expenditures. Despite potential progress in the treatment of heart failure, public health and clinical efforts should continue to target the prevention and treatment of high blood pressure and acute myocardial infarction—the two major, preventable underlying conditions associated with increased risk for heart failure. Primary prevention of heart failure includes adherence to everyday health practices associated with preventing hypertension and myocardial infarction (e.g., reduced dietary fat and/or sodium intake, moderate alcohol intake, weight maintenance, regular physical activity, and nonsmoking or smoking cessation). In addition, adults with hypertension should control blood pressure levels by improving daily health practices and using antihypertensive medications to prevent the development of heart failure.

ARTICLE INFORMATION

*Defined by the World Health Organization's International Classification of Diseases, Ninth Revision, as "(a) the disease or injury which initiated the train of morbid events leading directly to death, or (b) the circumstances of the accident or violence which produced the fatal injury."

REFERENCES

Thom  TJKannel  WB Congestive heart failure: epidemiology and cost of illness. Dis Manage Health Outcomes. 1997;175- 83
Link to Article
Croft  JBGiles  WHPollard  RACasper  MLAnda  RFLivengood  JR National trends in the initial hospitalization for heart failure. J Am Geriatr Soc. 1997;45270- 5
CDC, Mortality from congestive heart failure—United States, 1980-1990. MMWR. 1994;4377- 81
Manolio  TACutler  JAFurberg  CDPsaty  BMWhelton  PKApplegate  WB Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155829- 37
Link to Article
Pashos  CLNormand  SLTGarfinkle  JBNewhouse  JPEpstein  AMMcNeil  BJ Trends in the use of drug therapies in patients with acute myocardial infarction, 1988-1992. J Am Coll Cardiol. 1994;231023- 30
Link to Article
Garg  RYusuf  S Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;2731450- 6
Link to Article
Konstam  MADracup  KBaker  DW  et al.  Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction: clinical practice guideline no. 11.  Rockville, Maryland US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research1994;AHCPR publication no. 94-0612.
American College of Cardiology/American Heart Association Task Force, Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation. 1995;922764- 84
Link to Article
Croft  JBGiles  WHRoegner  RHAnda  RFCasper  MLLivengood  JR Pharmacologic management of heart failure among older adults by office-based physicians in the United States. J Fam Pract. 1997;44382- 90
Ghali  JKGiles  TGonzales  M  et al.  Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure. J La State Med Soc. 1997;149474- 84

Figures

Tables

References

Thom  TJKannel  WB Congestive heart failure: epidemiology and cost of illness. Dis Manage Health Outcomes. 1997;175- 83
Link to Article
Croft  JBGiles  WHPollard  RACasper  MLAnda  RFLivengood  JR National trends in the initial hospitalization for heart failure. J Am Geriatr Soc. 1997;45270- 5
CDC, Mortality from congestive heart failure—United States, 1980-1990. MMWR. 1994;4377- 81
Manolio  TACutler  JAFurberg  CDPsaty  BMWhelton  PKApplegate  WB Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155829- 37
Link to Article
Pashos  CLNormand  SLTGarfinkle  JBNewhouse  JPEpstein  AMMcNeil  BJ Trends in the use of drug therapies in patients with acute myocardial infarction, 1988-1992. J Am Coll Cardiol. 1994;231023- 30
Link to Article
Garg  RYusuf  S Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;2731450- 6
Link to Article
Konstam  MADracup  KBaker  DW  et al.  Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction: clinical practice guideline no. 11.  Rockville, Maryland US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research1994;AHCPR publication no. 94-0612.
American College of Cardiology/American Heart Association Task Force, Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation. 1995;922764- 84
Link to Article
Croft  JBGiles  WHRoegner  RHAnda  RFCasper  MLLivengood  JR Pharmacologic management of heart failure among older adults by office-based physicians in the United States. J Fam Pract. 1997;44382- 90
Ghali  JKGiles  TGonzales  M  et al.  Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure. J La State Med Soc. 1997;149474- 84
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 9

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles